Benjamin Lowentritt, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Astra Zeneca
    Date added:
    Date updated:
    07/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Abbvie
    Date added:
    Date updated:
    07/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Genomic Health
    Date added:
    Date updated:
    07/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    BlueEarth Diagnostics
    Date added:
    Date updated:
    07/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Merck
    Date added:
    Date updated:
    07/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    UroGen
    Date added:
    Date updated:
    07/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Pfizer
    Date added:
    Date updated:
    07/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Astellas
    Date added:
    Date updated:
    07/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Tolmar
    Date added:
    Date updated:
    07/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    UROGPO
    Date added:
    Date updated:
    07/24/2024

Pages

Return to PARP Inhibitors: Best Practices in Advanced Prostate Cancer Care in the Community Webcast (2021)